Case Study

A 730-Day Enrollment Window, Reshaped Before Day One 

A top-10 pharma sponsor's aggressive Phase III cardiovascular timeline, modeled head-to-head against real-world data — surfacing a diversified country mix that cut 118 days to LPI and raised success odds from 85% to 94%.

Enrollment Forecaster

🚧 Challenge: A top-10 pharma sponsor's Phase III cardiovascular program faced an aggressive enrollment timeline with limited confidence in its country and site allocation strategy.


🛠️ Approach: Using Enrollment Forecaster, the team stress-tested the original plan against real-world enrollment data and ran scenario models across alternative country mixes.


🏆 Outcome: A diversified country allocation cut projected time to last-patient-in (LPI) by 118 days and raised enrollment success probability from 85% to 94%—giving the sponsor a defensible, data-backed plan ahead of study start.

iStock
A-LIGN_SOC-2 Logo
image 10
image 8
attachment (3) 1
image 7
Group 3a02